Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    dksh-m-2025-05-26

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    An Enquiry

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Avutometinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Verastem Oncology Reports Positive Results from RAMP 205 Study
    Verastem Oncology Reports Positive Results from RAMP 205 Study

    22 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250522753974/en/Verastem-Oncology-Announces-Positive-Updated-Results-from-RAMP-205-Evaluating-Avutometinib-Plus-Defactinib-in-Combination-with-Standard-of-Care-Chemotherapy-in-Frontline-Metastatic-Pancreatic-Ductal-Adenocarcinoma

    BUSINESSWIRE
    22 May 2025
    Share Share
    Onco360 Chosen as National Specialty Pharmacy for AVMAPKI AKZY
    Onco360 Chosen as National Specialty Pharmacy for AVMAPKI AKZY

    12 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3079541/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-AVMAPKI-FAKZYNJA-CO-PACK.html

    GLOBENEWSWIRE
    12 May 2025
    Share Share
    FDA grants Verastem 1st approval for rare ovarian cancer treatment
    FDA grants Verastem 1st approval for rare ovarian cancer treatment

    09 May 2025

    // ENDPTS

    https://endpts.com/verastem-wins-first-fda-approval-for-ovarian-cancer-therapy/

    ENDPTS
    09 May 2025
    Share Share
    Verastem Announces KRAS Ovarian Cancer Launch, Debt Refinancing
    Verastem Announces KRAS Ovarian Cancer Launch, Debt Refinancing

    13 Jan 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250113992572/en

    BUSINESSWIRE
    13 Jan 2025
    Share Share
    Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer
    Verastem Announces FDA Acceptance for Avutometinib in Ovarian Cancer

    30 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241230294719/en

    BUSINESSWIRE
    30 Dec 2024
    Share Share
    Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
    Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer

    31 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241031747822/en

    BUSINESSWIRE
    31 Oct 2024
    Share Share